TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8710419

Group type: EXPERIMENTAL
Intervention: Targeted treatment with levamisole every 4 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Targeted treatment with levamisole at two 6-monthly intervals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Targeted treatment with levamisole once in 1 year
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated children (aged 0-4 years)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated adults
Number of subjects: 0
Study: 2000046

Group type: EXPERIMENTAL
Intervention: E + C 20 mg/200 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: E + C 10 mg/200 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: E + C 20 mg/100 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: E + C 10 mg/200 mg and E + C 20 mg/100 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: All combinations
Number of subjects: 6
Study: 6393621

Group type: EXPERIMENTAL
Intervention: 2 mg molsidomine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 6 mg molsidomine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 4 mg and 6 mg molsidomine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 2 mg molsidomine administered 5-6 times daily or 4-6 mg applied 4-5 times daily
Number of subjects: 12
Study: 31404020

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound + ERCP with minor papilla endoscopic sphincterotomy (miES)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Endoscopic ultrasound + sham
Number of subjects: 234
Study: 30816013

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD) in patients with ischaemic cardiomyopathy (ICM)
Number of subjects: 2293

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD) in patients with non-ischaemic cardiomyopathy (NICM)
Number of subjects: 2293
Study: 28500087

Group type: EXPERIMENTAL
Intervention: MACS decision rule
Number of subjects: 138

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Both groups (discharged within 4 hours)
Number of subjects: 138
Study: 25750106

Group type: EXPERIMENTAL
Intervention: TF-CBT with breathing biofeedback
Number of subjects: 8

Group type: COMPARATOR
Intervention: Regular TF-CBT
Number of subjects: 8
Study: 23901178

Group type: EXPERIMENTAL
Intervention: Endoscopic DCR
Number of subjects: 72

Group type: COMPARATOR
Intervention: External DCR
Number of subjects: 72
Study: 21434560

Group type: EXPERIMENTAL
Intervention: Group health education program
Number of subjects: 628
Study: 19241401

Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM) program
Number of subjects: 295

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 295
Study: 17098139

Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 25
Study: 15262833

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/d
Number of subjects: 3086

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3086
Study: 11697688

Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 9

Group type: COMPARATOR
Intervention: sham stimulation
Number of subjects: 9
Study: 9596110

Group type: EXPERIMENTAL
Intervention: Nebuhaler primed
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nebuhaler unprimed
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Volumatic primed
Number of subjects: 10

Group type: COMPARATOR
Intervention: Volumatic unprimed
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nebuchamber primed
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nebuchamber unprimed
Number of subjects: 10
Study: 7920958

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Lateral positions (45 degrees right lateral, 45 degrees left lateral)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Total group (all positions)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Coronary artery bypass graft and valve (closed or opened myocardium) subgroups
Number of subjects: 120

Group type: COMPARATOR
Intervention: Subgroups with and without lung disease
Number of subjects: 120
Study: 3402013

Group type: EXPERIMENTAL
Intervention: Droperidol 50 micrograms.kg‐1
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Droperidol 75 micrograms.kg‐1
Number of subjects: 65

Group type: COMPARATOR
Intervention: Standard oral premedication (meperidine 1.5 mg.kg‐1, diazepam 0.15 mg.kg‐1, atropine 0.02 mg.kg‐1)
Number of subjects: 65
Study: 29855293

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Harmful use of alcohol
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Insufficient intake of fruit and vegetable
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Low physical activity
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Overweight and obesity
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Dyslipidemia
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: At least one risk factor
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Exhibited six risk factors
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: At least three risk factors
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Caste/ethnicity
Number of subjects: 388
Study: 27147617

Group type: EXPERIMENTAL
Intervention: Formoterol (54 μg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 25786486

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS) during 6 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: No stimulation (control)
Number of subjects: 10
Study: 23727135

Group type: EXPERIMENTAL
Intervention: Dopamine D2 receptor occupancy levels
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Dopamine D2 receptor occupancy cut-off point
Number of subjects: 481
Study: 21914315

Group type: EXPERIMENTAL
Intervention: Shensongyangxin capsules + propafenone 150 mg, 3 times a day
Number of subjects: 349

Group type: COMPARATOR
Intervention: Propafenone 150 mg, 3 times a day
Number of subjects: 349
Study: 18795630

Group type: EXPERIMENTAL
Intervention: High-fat diet (HFD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High carbohydrate diet (HCD)
Number of subjects: 0
Study: 16432682

Group type: EXPERIMENTAL
Intervention: Quetiapine (50 mg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Olanzapine (5 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Haloperidol (3 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 12780462

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 11202222

Group type: EXPERIMENTAL
Intervention: Oral estrogen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transdermal estrogen
Number of subjects: 0
Study: 9175134

Group type: EXPERIMENTAL
Intervention: Deductive reasoning condition (determining entailment of sentences)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Inductive reasoning condition (assessing plausibility of sentences)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Inductive reasoning condition
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control condition (semantic comprehension of sentences)
Number of subjects: 10
Study: 1544011

Group type: EXPERIMENTAL
Intervention: Tacrine
Number of subjects: 0
Study: 7231666

Group type: EXPERIMENTAL
Intervention: Dominant hemisphere damaged (DH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nondominant hemisphere damaged (NDH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 0
Study: 31238785

Group type: EXPERIMENTAL
Intervention: Student pharmacist-led telephone follow-up intervention (weekly phone calls for 12 weeks)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 78
Study: 31157878

Group type: EXPERIMENTAL
Intervention: Early Limited Formula (ELF)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control
Number of subjects: 164
Study: 28611008

Group type: EXPERIMENTAL
Intervention: FAB (behavioral ED prevention program)
Number of subjects: 481

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 481
Study: 25273036

Group type: EXPERIMENTAL
Intervention: On-pump CABG
Number of subjects: 2303

Group type: COMPARATOR
Intervention: Off-pump CABG
Number of subjects: 2303

Group type: EXPERIMENTAL
Intervention: AF patients (both on-pump and off-pump)
Number of subjects: 2303
Study: 24016365

Group type: EXPERIMENTAL
Intervention: Stereoscopic visualization
Number of subjects: 31

Group type: COMPARATOR
Intervention: Monoscopic visualization
Number of subjects: 31
Study: 21343383

Group type: EXPERIMENTAL
Intervention: THC (2.5 mg, Marinol(®), twice daily for 18 days)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo (oral capsules, twice daily for 18 days)
Number of subjects: 46
Study: 19580960

Group type: EXPERIMENTAL
Intervention: Low expressed emotion (EE) carers
Number of subjects: 70

Group type: COMPARATOR
Intervention: High expressed emotion (EE) carers
Number of subjects: 70
Study: 17382619

Group type: EXPERIMENTAL
Intervention: Regional cerebral perfusion
Number of subjects: 77

Group type: COMPARATOR
Intervention: Deep hypothermic circulatory arrest
Number of subjects: 77
Study: 16832318

Group type: EXPERIMENTAL
Intervention: dexmethylphenidate extended-release (d-MPH-ER)
Number of subjects: 97

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 97
Study: 12708604

Group type: EXPERIMENTAL
Intervention: Dexibuprofen 800 mg daily
Number of subjects: 148

Group type: COMPARATOR
Intervention: Celecoxib 200 mg daily
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Dexibuprofen
Number of subjects: 148

Group type: COMPARATOR
Intervention: Celecoxib
Number of subjects: 148
Study: 10362151

Group type: EXPERIMENTAL
Intervention: Spermicidal film containing 72 mg of nonoxynol-9 per film
Number of subjects: 765

Group type: COMPARATOR
Intervention: Foaming tablet containing 100 mg of nonoxynol-9 per tablet
Number of subjects: 765
Study: 7498201

Group type: EXPERIMENTAL
Intervention: Ambulatory ST recordings before discharge
Number of subjects: 170

Group type: COMPARATOR
Intervention: Symptom-limited predischarge exercise test
Number of subjects: 170
Study: 1967717

Group type: EXPERIMENTAL
Intervention: Breast cancer screening by mammography and clinical examination
Number of subjects: 45130

Group type: EXPERIMENTAL
Intervention: Breast cancer screening in women aged 50 years and over
Number of subjects: 45130

Group type: COMPARATOR
Intervention: Routine mammography screening
Number of subjects: 45130

Group type: COMPARATOR
Intervention: Clinical examination alone as screening method
Number of subjects: 45130
Study: 7042364

Group type: EXPERIMENTAL
Intervention: Indoprofen (IP) 800 mg/die
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Indomethacin (IM) 200 mg/die
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Indomethacin (IM)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Indoprofen (IP)
Number of subjects: 102
Study: 30198329

Group type: EXPERIMENTAL
Intervention: POD FineVision
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: POD Toric FineVision
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: FineVision/MicroF
Number of subjects: 78
Study: 28369734

Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI)
Number of subjects: 46
Study: 26272770

Group type: EXPERIMENTAL
Intervention: Bevacizumab (15 mg/kg, every 3 weeks for six cycles) with neoadjuvant chemotherapy
Number of subjects: 1206

Group type: COMPARATOR
Intervention: Docetaxel plus capecitabine followed by doxorubicin plus cyclophosphamide
Number of subjects: 1206

Group type: COMPARATOR
Intervention: Docetaxel plus gemcitabine followed by doxorubicin plus cyclophosphamide
Number of subjects: 1206

Group type: COMPARATOR
Intervention: Docetaxel alone followed by doxorubicin plus cyclophosphamide
Number of subjects: 1206
Study: 23852909

Group type: EXPERIMENTAL
Intervention: Human FSH combined with recombinant FSH (group A)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Human FSH alone (group B)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Recombinant FSH alone (group C)
Number of subjects: 197
Study: 21457725

Group type: EXPERIMENTAL
Intervention: Advance notification letter followed by standard invitation
Number of subjects: 5000

Group type: COMPARATOR
Intervention: Standard invitation only
Number of subjects: 5000
Study: 18643808

Group type: EXPERIMENTAL
Intervention: Low-intensity, physician-endorsed dietary intervention
Number of subjects: 754
Study: 16598591

Group type: EXPERIMENTAL
Intervention: Trapidil 200 mg t.i.d.
Number of subjects: 648

Group type: COMPARATOR
Intervention: Isosorbide-dinitrate (ISDN) 20 mg b.i.d.
Number of subjects: 648
Study: 14600049

Group type: EXPERIMENTAL
Intervention: Revised Project ALERT drug prevention program (11 lessons in 7th grade and 3 in 8th grade)
Number of subjects: 4276

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 4276
Study: 10809919

Group type: EXPERIMENTAL
Intervention: TGA patients, P3 latency measured at vertex (Cz electrode) in visual paradigm
Number of subjects: 18

Group type: COMPARATOR
Intervention: TIA patients, P3 latency measured at vertex (Cz electrode) in visual paradigm
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group, P3 latency measured at vertex (Cz electrode) in visual paradigm
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: TGA patients, P3 latency measured at vertex (Cz electrode) in auditory paradigm
Number of subjects: 18

Group type: COMPARATOR
Intervention: TIA patients, P3 latency measured at vertex (Cz electrode) in auditory paradigm
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group, P3 latency measured at vertex (Cz electrode) in auditory paradigm
Number of subjects: 18
Study: 8980985

Group type: EXPERIMENTAL
Intervention: THRESHOLD trainer
Number of subjects: 10

Group type: COMPARATOR
Intervention: Weighted plunger (WP)
Number of subjects: 10
Study: 1613700

Group type: EXPERIMENTAL
Intervention: recombinant tissue plasminogen activator (rtPA)
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study: 6853155

Group type: EXPERIMENTAL
Intervention: Traditional Chinese acupuncture
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 16
Study: 31243022

Group type: EXPERIMENTAL
Intervention: Group choir singing (n=29), 90 min weekly sessions for 12 weeks
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (n=29), non-intervention
Number of subjects: 58
Study: 29696422

Group type: EXPERIMENTAL
Intervention: Open-mouth exercise device
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Conventional group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 30421393

Group type: EXPERIMENTAL
Intervention: IV paracetamol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 0
Study: 27614373

Group type: EXPERIMENTAL
Intervention: Triple-application practice (TAP) group
Number of subjects: 156

Group type: COMPARATOR
Intervention: Single-application practice (SAP) group
Number of subjects: 156
Study: 24263695

Group type: EXPERIMENTAL
Intervention: CT at 340 mAs with filtered back‐projection and sinogram‐affirmed iterative reconstruction (S1-S5)
Number of subjects: 94

Group type: COMPARATOR
Intervention: CT at 260 mAs with filtered back‐projection and sinogram‐affirmed iterative reconstruction (S1-S5)
Number of subjects: 94
Study: 22616576

Group type: EXPERIMENTAL
Intervention: Algorithm based on administrative data with three criteria: a) discharged patients with a chronic lung-disease diagnosis at least once during the preceding 5 years; b) redeemed prescription of lung-medication at least twice during the preceding 12 months; c) at least two spirometries performed at different dates during the preceding 12 months.
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Algorithm based on administrative data.
Number of subjects: 266
Study: 20615491

Group type: EXPERIMENTAL
Intervention: Priming for innovativeness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Priming involving additional AA-relevant dimensions
Number of subjects: 0

Group type: COMPARATOR
Intervention: No specific control group mentioned
Number of subjects: 0
Study: 17437872

Group type: EXPERIMENTAL
Intervention: RoekoSeal (silicone‐based)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: AH‐Plus (epoxy‐resin‐based)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Roth's sealer (zinc oxide eugenol‐based)
Number of subjects: 95
Study: 15224025

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1 g as 20-minute bolus before skin incision, followed by continuous infusion of 400 mg/h, with 500 mg added to priming in on-pump patients)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo (saline solution of equivalent volume)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 102
Study: 11759645

Group type: EXPERIMENTAL
Intervention: Valsartan (160 mg twice daily)
Number of subjects: 5010

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5010
Study: 9399611

Group type: EXPERIMENTAL
Intervention: Community pharmacist intervention
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 51
Study: 7708529

Group type: EXPERIMENTAL
Intervention: Cryptorchid patients
Number of subjects: 517

Group type: COMPARATOR
Intervention: Control group (boys who underwent inguinal exploration)
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Adults operated on for bilateral cryptorchidism
Number of subjects: 517
Study: 3502173

Group type: EXPERIMENTAL
Intervention: 0.03% flurbiprofen
Number of subjects: 72

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 72
Study: 29798889

Group type: EXPERIMENTAL
Intervention: Black participants
Number of subjects: 8309

Group type: COMPARATOR
Intervention: White participants
Number of subjects: 8309

Group type: COMPARATOR
Intervention: Black participants vs White participants
Number of subjects: 8309
Study: 27062948

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Medical treatment as usual, delayed treatment (DT) control
Number of subjects: 24
Study: 25690404

Group type: EXPERIMENTAL
Intervention: Pulsed RF EMF exposure (900 MHz, 2 Hz pulse, 20 Hz Gaussian low-pass filter, spatial peak absorption of 2 W/kg averaged over 10 g) for 30 minutes prior to sleep
Number of subjects: 20
Study: 23615825

Group type: EXPERIMENTAL
Intervention: 5-15 g alcohol/d (about one drink)
Number of subjects: 93676

Group type: EXPERIMENTAL
Intervention: Cumulative average alcohol intake
Number of subjects: 93676

Group type: EXPERIMENTAL
Intervention: Most recent alcohol intake
Number of subjects: 93676

Group type: COMPARATOR
Intervention: Total caffeine intake, cups of caffeinated coffee, decaffeinated coffee, and caffeinated tea
Number of subjects: 93676
Study: 20948487

Group type: EXPERIMENTAL
Intervention: Intermittent catheterization
Number of subjects: 75

Group type: COMPARATOR
Intervention: Suprapubic catheterization
Number of subjects: 75
Study: 19026794

Group type: EXPERIMENTAL
Intervention: Perimount valve
Number of subjects: 99

Group type: COMPARATOR
Intervention: Mosaic valve
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Both valves
Number of subjects: 99
Study: 16799824

Group type: EXPERIMENTAL
Intervention: Telos device
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hamstring contraction
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Kneeling view
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Gravity view
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Axial view
Number of subjects: 30
Study: 12712239

Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated) 24 micro g/kg per hour for 96 h
Number of subjects: 1271

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1271

Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated)
Number of subjects: 1271
Study: 10344368

Group type: EXPERIMENTAL
Intervention: Transdermal oestradiol with cyclic addition of noretisterone acetate (n = 13)
Number of subjects: 23
Study: 8786543

Group type: EXPERIMENTAL
Intervention: Clonidine (0.4-0.5 mg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Naloxone (0.2 or 0.4 mg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 7
Study: 1956490

Group type: EXPERIMENTAL
Intervention: Cellulosic membranes (Cuprophan, CUP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Synthetic polyacrilonitrile membranes (PAN AN-69)
Number of subjects: 20
Study: 7086102

Group type: EXPERIMENTAL
Intervention: pH 1 citric acid
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 0.15 mM hydrochloric acid
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: pH 7 sodium citrate
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: pH 0.85 hydrochloric acid
Number of subjects: 13

Group type: COMPARATOR
Intervention: Normal subjects (control)
Number of subjects: 13
Study: 30124989

Group type: EXPERIMENTAL
Intervention: Olanzapine (5 mg) plus standard triple antiemetic therapy
Number of subjects: 690

Group type: COMPARATOR
Intervention: Placebo plus standard triple antiemetic therapy
Number of subjects: 690
Study: 26247548

Group type: EXPERIMENTAL
Intervention: Climbing intervention (10 sessions in 8 weeks, at least once a week for a minimum duration of 1 hour)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 30
Study: 25187581

Group type: EXPERIMENTAL
Intervention: Periarticular injection
Number of subjects: 111
Study: 22753306

Group type: EXPERIMENTAL
Intervention: Blacks (age-adjusted HR=1.45)
Number of subjects: 156143

Group type: COMPARATOR
Intervention: Whites (age-adjusted HR=1.00, reference group)
Number of subjects: 156143

Group type: EXPERIMENTAL
Intervention: Hispanics (age-adjusted HR=0.72)
Number of subjects: 156143

Group type: EXPERIMENTAL
Intervention: Asian/Pacific Islanders (age-adjusted HR=0.44)
Number of subjects: 156143

Group type: EXPERIMENTAL
Intervention: Adjustment for household income (HR=0.97) and diabetes mellitus (HR=0.89) in blacks
Number of subjects: 156143

Group type: EXPERIMENTAL
Intervention: Adjustment for traditional risk factors, socioeconomic status, lifestyle, and access-to-care variables
Number of subjects: 156143